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Abstract
Human embryonic stem cell-derived endothelial cells (hESC-EC), as well as other stem cell derived endothelial cells, have a
range of applications in cardiovascular research and disease treatment. Endothelial cells sense Gram-negative bacteria via
the pattern recognition receptors (PRR) Toll-like receptor (TLR)-4 and nucleotide-binding oligomerisation domain-
containing protein (NOD)-1. These pathways are important in terms of sensing infection, but TLR4 is also associated with
vascular inflammation and atherosclerosis. Here, we have compared TLR4 and NOD1 responses in hESC-EC with those of
endothelial cells derived from other stem cells and with human umbilical vein endothelial cells (HUVEC). HUVEC, endothelial
cells derived from blood progenitors (blood outgrowth endothelial cells; BOEC), and from induced pluripotent stem cells all
displayed both a TLR4 and NOD1 response. However, hESC-EC had no TLR4 function, but did have functional NOD1
receptors. In vivo conditioning in nude rats did not confer TLR4 expression in hESC-EC. Despite having no TLR4 function,
hESC-EC sensed Gram-negative bacteria, a response that was found to be mediated by NOD1 and the associated RIP2
signalling pathways. Thus, hESC-EC are TLR4 deficient but respond to bacteria via NOD1. This data suggests that hESC-EC
may be protected from unwanted TLR4-mediated vascular inflammation, thus offering a potential therapeutic advantage.
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Introduction
Endothelial cells line the luminal surface of blood vessels and
provide a physical and metabolic barrier between the vessel and
the circulation, and are essential for cardiovascular homeostasis. In
health, endothelial cells release vasoactive hormones including
prostacyclin and nitric oxide, which regulate smooth muscle and
platelet function [1]. Endothelial cells are also a key cell type in
innate immunity, and express pattern recognition receptors
(PRRs), including Toll like receptors (TLRs) and nucleotide-
binding oligomerization domain-containing protein (NOD) recep-
tors [2–4]. Gram-negative bacteria are sensed by two key PRRs,
TLR4, which recognises lipopolysaccharide (LPS), and NOD1,
which recognises moieties in peptidoglycan. Activation of endo-
thelial cells by pathogens is an early event in innate immunity,
resulting in the expression of adhesion receptors and the release of
chemokines [5,6]. This allows for immune cells to be recruited to
an area of infection, and for subsequent pathogen killing, removal
and resolution. However, PRRs on endothelial cells, including
TLR4 and TLR2, have also been associated with vascular
inflammation and cardiovascular disease, such as atherosclerosis
[7–9].
The therapeutic potential of stem cell-derived endothelial cells is
increasingly recognised. As such, endothelial cells derived from
stem cells are currently being investigated as cell therapies for a
number of conditions, including cardiovascular disease [10]. The
most common sources of stem cells that can be differentiated to
endothelial cells include embryonic stem cells, induced pluripotent
stem cells and adult progenitor stem cells; each with benefits and
limitations. Understanding how stem cell-derived endothelial cells
function at both the cardiovascular and immune level will be
essential in the arena of cell therapy and organ regeneration,
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where new vessel and vascular network construction underlies the
basis of clinical benefit.
We have previously shown that endothelial cells derived from
human embryonic stem cells (hESC-EC) express an immature
immune phenotype, with no discernible TLR4 function [11]. We
have speculated that this may provide an advantage since TLR4
on endothelial cells is directly linked to atherosclerosis [10,11].
However, lack of TLR4 could result in endothelial cells not being
able to sense pathogens, and render tissue/organs immune-
suppressed and thereby susceptible to infection with Gram-
negative bacteria. In the current study we have confirmed our
previous work that hESC-EC do not express functional TLR4
responses. For the first time, we have compared TLR4 and NOD1
functions in endothelial cells derived from three key stem cell
sources; embryonic stem cells, adult progenitors (blood outgrowth
endothelial cells; BOEC) and induced pluripotent stem cell derived
endothelial cells (iPSC-EC). We also extend our previous work by
showing that hESC-EC remain devoid of TLR4 after a period of
in vivo ‘conditioning’ in nude rats. We have gone on to investigate
the functionality of NOD1 receptors in hESC-EC and whether,
through NOD1 signalling, hESC-EC can sense live Gram-
negative bacteria.
Materials and Methods
Media and Solutions
Lonza-EGM2 media was prepared by addition of Lonza-EGM2
SingleQuot supplements and growth factors to Lonza-EBM2 basal
medium (Lonza, Belgium). Information of the concentrations of
additions in ‘SingleQuot supplements and growth factors’ are not
available, however, supplier’s information states the following are
included; human epidermal growth factor (hEGF), gentamicin-
amphotericin-B 100, R3- insulin growth factor (IGF)-1, ascorbic
acid, vascular endothelial cell growth factor (VEGF), human
fibroblast growth factor (hFGF)-B, heparin, hydrocortisone. The
media was prepared according to the supplier’s instructions except
that the recommended 2% foetal bovine serum (FBS) supplied
with the kit was replaced and increased to 10% using FBS from
Hyclone (HYC-001-330Y, Thermo Scientific, Massachusetts,
USA). Type-1 rat tail collagen solution (#35423, Becton
Dickinson, New Jersey, USA) was prepared in 0.02N glacial
acetic acid, according to manufacturer’s instructions, at a
concentration of 50 mg/ml and used to pre-coat surfaces used
for blood outgrowth endothelial cell (BOEC) isolation and
maintenance. Coating was achieved by adding 5.2 mg/cm2
collagen solution and incubating at 37uC, 5% CO2 for 1 hour
prior to washing three times with PBS.
hESC-EC
Experiments were carried out using the H7 hESC line provided
under collaboration agreement with the Geron Corporation
(Menlo Park, CA, USA) and with permission of the UK Stem
Cell Bank. All ethical approvals had been acquired. hESC were
maintained in their undifferentiated state as described previously
[12] and as instructed by Geron. Briefly, hESC were grown on
Matrigel (BD Biosciences) coated 6-well plates in mouse embry-
onic fibroblast conditioned medium supplemented with 8 ng/ml
basic fibroblast growth factor.
Differentiation of hESC into hESC-EC was carried out as
described previously [11]. Briefly, cells were dissociated into
clumps and plated on ultra-low attachment plates (Nunc, Den-
mark) with Lonza-EGM2 to allow formation of embryoid bodies.
After 4 days embryoid bodies were re-plated on 1% gelatinized
(1% gelatin) (Sigma-Aldrich, St Louis, USA) 6-well plates in
Lonza-EGM2. After 13 days cells were stained for CD31 using an
Alexa Fluor 488 fluorescence dye labelled anti-CD31 antibody
(BD Biosciences, Oxford, UK). Cells were sorted using a FACS
Aria II cell sorter (BD Biosciences, Oxford, UK) and expanded in
Lonza-EGM2 medium for further use.
Blood outgrowth endothelial cells (BOEC)
BOEC were isolated as published elsewhere [13–17] with minor
modifications. Briefly, blood (48 ml) was collected into tubes with
Ficoll [18], from healthy volunteers aged 24–45 and centrifuged at
1600 RCF for 30 minutes at room temperature with maximum
acceleration and braking rates to obtain PBMCs. Tubes were then
inverted 8 times prior to centrifugation, and after centrifugation to
allow mixing of the buffy coat and plasma/serum fraction.
Contents were then carefully pooled into a 50 ml falcon tube and
10% FBS/PBS added to give a final volume of 50 ml. Cells were
then centrifuged at 520 RCF for 10 minutes with maximal
acceleration and intermediate braking. The supernatant was
discarded and pellets resuspended in 10 ml of 10% FBS/PBS
solution. This process was repeated a further two times giving
three washes in total. Prior to the final centrifugation 10 ml of cell
suspension was added to a haemocytometer for counting. After the
final wash cells were subsequently resuspended in an appropriate
amount of Lonza-EGM2 with 10% FBS and distributed across
collagen pre-coated wells of a 6-well plate (Nunc, Denmark) at a
density of 36107 cells/well. Plates were incubated at 37uC, 5%
CO2. After 24 hours media was carefully removed, cells were
washed with Lonza-EGM2 10% FBS and 4 ml of fresh Lonza-
EGM2 10% FBS added to each well. This process was repeated
every 48 hours for 4 days then every 24 hours until day 7. After
day 7 media was replaced every other day without washing until
colonies appeared. Colonies of endothelial cells typically emerged
between days 7–20. Once colonies emerged they were allowed to
expand for not more than 3–5 days. Colonies were removed by
trypsin (TrypLE 16) digest using 2 ml trypsin/well. Trypsin was
neutralised with 4 ml Lonza-EGM2 10%FBS and the 6 ml cell/
trypsin mix collected in a 50 ml falcon tube and centrifuged at 190
RCF for 5 minutes at room temperature with maximal acceler-
ation and intermediate break settings. Cells were then plated on
expanded and maintained on T25 and T75 culture flasks (Nunc,
Denmark) pre-treated with collagen as described above.
Human umbilical vein endothelial cells (HUVEC)
HUVEC were a gift from Caroline Wheeler-Jones (Royal
Veterinary College, London), and were isolated as described
previously [19]. Cells were maintained in Lonza-EGM2 medium.
Cells were at passage 2 on arrival and used for experiments
between passage 2–8. HUVEC were grown on gelatinized (1%
gelatin) (Sigma-Aldrich, St Louis, USA) T75 flasks.
Induced pluripotent stem cell derived-endothelial cells
(iPSC-EC)
IPSC-EC used in this study were purchased from Cellular
Dynamic International (Madison, USA). Cells were maintained in
Lonza-EGM2 on fibronectin (Invitrogen, California, USA) coated
T75 flasks according to manufacturer’s instructions.
Treatment protocols
Cells were plated on 1% gelatinised 96-well plates (Nunc,
Denmark) and grown to confluence. Cells were seeded at a density
of 7,000cells/well and confluence was defined as 80–100%
coverage. Time to reach confluence was approximately 48 hours.
Cells were then treated with media alone or media +/2 LPS (0.1–
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1 mg/ml) (Invivogen, California, USA), C12-iE-DAP [20] (Laur-
oyl-c-D-Glu-mDAP) (1–10 mg/ml) (Invivogen, California, USA) or
IL-1b (0.1–1 ng/ml) (R & D systems, Abingdon, UK) for 1 or
24 hours. Where responses of cells were compared directly,
different endothelial cell types were plated in the same media
and treated under identical conditions. The RIP2 inhibitor
GSK’214 and the NOD1 inhibitor GSK’217 were provided by
GlaxoSmithKline (Philadelphia, USA). Precise structural details
for GSK2576214A (GSK’214) and GSK1219217A (GSK’217)
were not available to us at this time. Cells were incubated with
inhibitors for 30 minutes prior to addition of agonists. Drugs were
dissolved initially in dimethyl sulphoxide (except for LPS which
were dissolved in PBS) to prepare stock solution. Further dilutions
were made in Lonza-EGM2 with 10% FBS.
siRNA knockdown of NOD1
For NOD1 siRNA knockdown protocols, targeting NOD1
siRNA (Hs_CARD4_1 Flexitube siRNA (NM_006092); Qiagen,
Crawley, UK) was used according to manufacturer’s instructions.
Cells were plated 24 hours before transfection. Final concentration
of siRNA was 25 nM. Scrambled non-targeting siRNA (25 nM;
Qiagen, Crawley,UK) was used as negative controls. Following
48 hour transfection supernatants were collected for analysis and
cells lysed with TriReagent buffer (Sigma-Aldrich, Abingdon, UK)
for total RNA extraction. Expression of NOD1 was determined as
described below.
Endothelial cell infection assay
Cells were untreated or inoculated with live Haemophilus
influenzae (ATTC strain 49247), which is a Gram-negative
bacterium. Haemophilus influenzae was used at colony forming unit
dilutions of 108–105 for 24 hours. In these experiments a ‘filter
control’ was also included. This control represents a bacteria free
conditioned media produced by filtering cultures through a 30-
kDa membrane (Ultrafree-0.5 PBTK Centrifugal Filter Unit
30 kDa Millipore UFV5BTK00) (Millipore, Gloucestershire, UK).
Figure 1. TLR4 and NOD1 expression and function in stem cell derived endothelial cells. (A) TLR4 and NOD1 expression in hESC-EC
(relative to expression in HUVEC) in vitro. Data are mean 6 SEM (n= 3). Statistical significance was determined by one-sample t-test (*p,0.05) for
NOD1 vs. TLR4 expression. (B) Representative immunocytochemistry images of hESC-EC (top) and HUVEC (bottom) stained for the NF-kB p65-subunit
(red) in response to 1 hour treatment with or without, C12-iE-DAP (NOD1 agonist; 10 mg/ml), LPS (TLR4 agonist; 1 mg/ml) or IL-1b (1 ng/ml). Nuclei
were stained with DAPI (blue; 5 mg/ml). Images were acquired using a Cellomics VTi HCS Arrayscanner with a CarlZeiss microscope. (C) LPS (TLR4
agonist; 1 mg/ml) and C12-iE-DAP (NOD1 agonist; 10 mg/ml) induced CXCL8 release after 24 hour stimulation. Data are mean 6 SEM. For HUVEC,
hESC-EC or BOEC, n = 4–8. For iPSC-EC, n = 2, single isolation. Statistical significance was determined by one-way ANOVA followed by Dunnett’s
multiple comparison test for each cell type (*p,0.05) and by two-way ANOVA followed by Bonferroni’s post-test for between cell types. Analysis was
not performed on data from iPSC-EC.
doi:10.1371/journal.pone.0091119.g001
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Measurement of CXCL8
CXCL8 (IL8) was measured by ELISA (Duoset CXCL8 Kit,
DY208E; R & D Systems, Abingdon UK), according to
manufacturer’s instructions.
Measurement of cytokine array using MSD platform
The following cytokines were measured using the human pro-
inflammatory 9-Plex MULTISPOT 96-well 210 spot MSD assay
(Gaithersburg, Maryland, USA) (Cat no. N05007A-1); IL-2, IL-8,
IL-12p70, IL-1b, GM-CSF, IFNc, IL-6, IL-10 and TNFa.
Selected samples from various experiments were diluted 1:10 in
Lonza-EGM2 and added to the MSD plate. The immunoassay
was carried out according to manufacturer’s instructions. Plates
were read using an MSC Sector Imager 2400 and analysed using
MSD Discovery Workbench software.
Measurement of NF-kB translocation
Cells were treated for 1 hour with drugs as above, washed with
PBS and fixed immediately in 4% para-formaldehyde (PFA) for
10 minutes at room temperature. Plates were then washed three
times with PBS at 5 minute intervals. Plates were permeabilized
with 0.2% Triton X-100 for 10 minutes and blocked with 4%
foetal bovine serum (FBS) in PBS for 1 hour at room temperature.
For NF-kB staining, cells were incubated with NF-kB-p65
(human) primary antibodies raised in rabbit (Santa Cruz
Biotechnology, UK) for 1 hour at room temperature followed by
secondary staining with AlexaFluor 546 anti-rabbit antibodies
raised in goat (Invitrogen, UK) for 45 minutes at room temper-
ature. Cells were washed three times between incubations with
PBS at 5 minute intervals. Cell nuclei were stained with DAPI.
Plates were then stored in PBS at 24uC prior to imaging using a
Cellomics VTi HCS Arrayscanner (camera make/model: Arrays-
can 12bit dynamic range high resolution thermo-cooled with a
Zeiss Plan Neurofluour objective lens) (Thermo Fisher, Pittsburgh,
USA). Some wells were treated with secondary antibody only to
establish background auto fluorescence. Images were acquired at
610 magnification at room temperature with PBS as imaging
medium.
In vivo conditioning of cells using transplantation in
Matrigel
HESC-EC and HUVEC were expanded in vitro and 106 cells
were injected subcutaneously into 3-month-old athymic nude rats
(Crl:NIH-Foxn1rnu, Charles River) in a suspension of 50 ml
Matrigel (Becton Dickinson, Massachusetts, USA), heparin
(64 U/ml), recombinant murine basic FGF (80 ng/ml, R & D
Systems), 70 ml Lonza-EGM2. A matrigel suspension with no cells
served as negative control. After 3 weeks, rats were sacrificed and
plugs removed, photographed and stored for cryosectioning and
RNA isolation. Animals used (n = 24) were RNU rats, Crl:NIH-
Foxn1rnu, stain code 316. Anaesthetics ketamine (Richter Gedeon
Pharmaceutical Company, Budapest, Hungary; 75 mg/kg, ip) and
xylazine (Produlab Pharma, Rammsdonksveer, Netherlands;
5 mg/kg, ip) were used in surgical procedures.. Matrigel plugs
with cells were lysed in TriReagent for total RNA extraction. The
RNA was purified using RNeasy columns (Qiagen, Hilden,
Germany), quantified, and checked for quality. 500 ng of total
RNA was used for DNA generation using High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, California, USA)
according to manufactures instructions.
Quantitative Real time PCR (qRT-PCR) for TLR4 and NOD1
expression
For the PCR array (expression of TLR4 shown; Figure 1A) the
cDNA was hybridized in a 96-well format against the Gene Array
PAHS-058 with RT2 qPCR Master Mix, which contained SYBR
green dye (RT2 Profiler PCR Array System, SABiosciences) as per
the manufacturer’s instructions. Data were normalised to the
mean of 5 housekeeping genes included in the array (B2M,
HPRT1, RPL13A, GAPDH, ACTB). Expression of NOD1
(shown in Figure 1A) was determined by qRT-PCR where RNA
levels were determined using a NanoDrop platform and used to
normalise loading of RNA prior to reverse transcription to cDNA
for analysis. Data were normalised to GAPDH as a housekeeping
geneThe PCR was performed with ABI 5700 (Applied Biosystems,
CA) and Rotor-Gene 3000 (Corbett Research) real-time PCR
instruments, and the relative expression was determined by DDCt
method in which fold change = 22DDCt.
For quantifying mRNA levels of NOD1/CARD4
(Hs00196075_m1), and TLR4 (Hs00152939_m1) in hESC-EC
pre- and post-implant and following NOD1-siRNA, real-time
PCR analyses were performed with TaqMan Gene Expression
Assays (Applied Biosystems, CA) using human-specific primers.
GAPDH Endogenous Control (FAM/MGB probe) was used as a
housekeeping control. Relative gene expression was determined by
DDCt method in which fold increase = 22DDCt.
Statistical analysis
All data is the mean 6 S.E.M. for n separate incubations of
individually treated cells. Unless otherwise stated all experiments
were at least n = 3 and experiments were performed on at least 2
separate isolations of cells with separately prepared drugs or
bacteria. Analysis was performed using GraphPad Prism software
as described in each figure legend.
Ethics Statement
Experiments using hESC and isolation of hESC-EC were
approved by the UK Stem Cell bank. For the collection of human
blood and the protocol for isolation of BOEC, ethical approval
was granted by the Royal Brompton and Harefield Ethics
Table 1. MSD analysis of cytokine (pg/ml) release from hESC-EC.
Analyte
(pg/ml) GM-CSF IFNc IL-10 IL-12p70 IL-1b IL-2 IL-6 TNFa CXCL8
CONTROL 30.362.5 ND 1.660.4 8.063.6 0.860.3 65.965.9 90.9614.5 ND 1566.56160.0
+ C12-iE-DAP 160.9645.3* 11.167.1 6.061.7 83.7630.3* 11.961.1* 303.9664.8* 295.5678.1* 4.860.2* 9569.162645.2*
+ LPS 20.960.5 ND 1.960.3 12.963.2 2.161.2 62.664.0 104.869.1 ND 1691.86120.3
Data mean are 6 SEM for n = 3. hESC-EC were treated for 24 hours with vehicle, LPS (1 mg/ml), or C12-iE-DAP (10 mg/ml). Statistical significance was determined by one-
way ANOVA followed by Dunnett’s multiple comparison test (*p,0.05). ND= non-detectable.
doi:10.1371/journal.pone.0091119.t001
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Committee (ethics code: 08/H0708/69). Informed written consent
was given by all participants. The consent procedure, and
associated patient information sheets and consent forms, were
approved by the Royal Brompton and Harefield Ethics Commit-
tee. Consent records were maintained as required by the Royal
Brompton and Harefield Ethics Committee. For in vivo experi-
ments using animals, the Animal Use and Care Committee of
Semmelweis University Budapest approved the experimental
protocols (Ref no. 22.1/1098/3/2011). The investigation con-
formed to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health.
Results
Cytokine, TLR4 and NOD1 agonist induced responses in
hESC-EC, BOEC, iPSC-EC and HUVEC
We have previously shown that, whilst hESC-EC do not
respond to TLR agonists (apart from TLR5) [11], they do express
all of the necessary intracellular signalling to mount an immune/
inflammatory response, and respond avidly to IL-1b [11]. Here we
confirm our previous observations and show that hESC-EC
expressed much lower levels of TLR4 than HUVEC (Figure 1A)
and do not respond to LPS (Figure 1B and C). However, we show,
for the first time, that hESC-EC do express a second PRR for
Gram-negative bacteria, NOD1 (Figure 1A). In line with this, the
NOD1 agonist C12-iE-DAP activated hESC-EC, causing nuclear
translocation of NF-kB and release of CXCL8 (Figure 1B and C).
Endothelial cells from umbilical veins (HUVEC) or derived from
blood progenitors (BOEC) or from induced pluripotent stem cells
(iPSC-EC) responded to both LPS and C12-iE-DAP (Figure 1C).
In order to be sure that the lack of response to LPS seen at the
level of CXCL8 was not specific to this chemokine, we measured
release of a range of other cytokines (GM-CSF, IFNc, IL-10, IL-
12p70, IL-1b, IL-2, IL-6, TNFa), and found identical responses
(Table 1 and 2). The NOD1 agonist, C12-iE-DAP induced release
of GM-CSF, IL-12q70, IL-2, IL-6, IL1b and TNFa from hESC-
EC with no effect seen with LPS (Table 1 and 2).
Effect of in vivo conditioning of hESC-EC following
implantation into nude rats
The hESC-EC used here were differentiated into endothelial
cells using standard protocols and, as we have shown previously,
display hallmarks of mature endothelial cells [11]. However, in
order to establish if TLR4 expression could be induced in vivo, cells
were transplanted into nude rats and ‘conditioned’ for 21 days.
This approach has been shown by others to result in vessel
formation of hESC-EC in vivo [21,22]. However, after transplant in
vivo, TLR4 was not increased in hESC-EC or in HUVEC
(Figure 2). By contrast, NOD1 expression tended to be increased
in both hESC-EC and HUVEC after in vivo conditioning. These
observations suggest that hESC-EC will retain an immune
privileged phenotype for TLR4 and an active NOD1 pathway
when transplanted in vivo.
Responses of hESC-EC and HUVEC to Haemophilus
influenzae infection
As discussed, Gram-negative bacteria are sensed by two key
PRR pathways: TLR4, which is the receptor for LPS, and NOD1,
which is the receptor for peptidoglycan moieties. As with other
Table 2. MSD analysis of cytokine (pg/ml) release from HUVEC.
Analyte (pg/ml) GM-CSF IFNc IL-10 IL-12p70 IL-1b IL-2 IL-6 TNFa CXCL8
CONTROL 37.061.6 2.861.0 1.461.2 12.960.9 1.360.6 69.3619.2 63.7620.4 0.560.3 1500.66351.5
+ C12-iE-DAP 190.0644.8 7.963.0 2.761.1 60.2612.5* 7.063.3 198.2626.3* 213.1665.1 1.760.9 6044.16960.3*
+ LPS 279.6115.5 5.161.3 4.760.6 38.765.0 5.662.4 223.1634.3* 323.86114.2 1.861.0 6154.46857.6*
Data are mean 6 SEM for n = 3. HUVEC were treated for 24 hours with vehicle, LPS (1 mg/ml), or C12-iE-DAP (10 mg/ml). Statistical significance was determined by one-
way ANOVA followed by Dunnett’s multiple comparison test (*p,0.05).
doi:10.1371/journal.pone.0091119.t002
Figure 2. Effect of in vivo ‘conditioning’ on TLR4 and NOD1 expression. TLR4 and NOD1 expression in (A) hESC-EC and (B) HUVEC before
(pre-implant; open bars) and 21 days after (post-implant; filled bars) implantation in vivo (‘conditioning’). Data are mean6 SEM and are normalized at
unity (1) to gene levels in pre-implant cells. HUVEC; NOD1 pre-implant n = 8, post implant n = 4: HUVEC; TLR4 pre-implant n = 10, post implant n= 3.
hESC-ECs; NOD1 pre-implant n = 6, post implant n= 5: hESC-ECs; TLR4 pre-implant n = 10, post implant n = 6. Data was obtained from 2 independent
experiments (using up to 12 rats per group). Statistical significance was determined by one-sample t-test where results were compared to a
theoretical control of 1 (*p,0.05). ND=none detectable.
doi:10.1371/journal.pone.0091119.g002
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types of Gram-negative bacteria, Haemophilus influenzae is report-
edly sensed by cells via TLR4 and/or NOD1 PRR pathways
[23,24]. However, the relative contribution of TLR4 versus
NOD1 to sensing of whole live Gram-negative bacteria will vary
depending upon the cell type. In order to test the potential for
hESC-EC to sense bacteria, despite no TLR4, we infected hESC-
EC and HUVEC with live Gram-negative bacteria (Haemophilus
influenzae). In these experiments, as with others, basal release of
CXCL8 was relatively low in both cell types and again, LPS
activated HUVEC, but not hESC-EC, whilst C12-iE-DAP
activated both cell types (Figure 3A). However, despite no TLR4
function, infection of hESC-EC with live Haemophilus influenzae
induced a concentration-dependent release of CXCL8 (Figure 3B).
Importantly, the potency and efficacy of Haemophilus influenzae to
induce CXCL8 release was found to be comparable between
hESC-EC and HUVEC (Figure 3). These results suggest that, in
hESC-EC, NOD1 receptors are sufficient to accommodate the
sensing of Gram-negative bacteria. In order to establish the role of
NOD1 receptors in the activation of hESC-EC by Haemophilus
influenzae, we took a molecular approach using gene knock down,
and a pharmacological approach using selective inhibitors.
Role of NOD1 in hESC-EC responses to C12-iE-DAP and
Gram-negative bacteria
NOD1 receptors can be knocked down using conventional
targeting siRNA. In addition, novel NOD1 and RIP2 inhibitors
have been developed by GSK, which we have previously used and
validated [25]. We have shown that the NOD1 antagonist
GSK’217 inhibits NOD1, without affecting TLR4 in endothelial
cells [25], and that the RIP2 inhibitor GSK’214 also blocks NOD1
without affecting TLR4 responses in these cells [25]. Here we
show, as expected, that knocking down NOD1 receptors at the
gene level (Figure 4A) inhibited responses in hESC-EC to the
NOD1 agonist C12-iE-DAP and, importantly, also to Haemophilus
influenzae infection (Figure 4B). In line with this, inhibiting NOD1
with GSK’217 or RIP2 with GSK’214 reduced CXCL8 release
from Haemophilus influenzae infected or C12-iE-DAP treated cells
(Figure 4C). CXCL8 levels from IL-1b treated hESC-EC were not
affected by NOD1 siRNA (Figure S1) or the NOD1 (GSK’217)
and RIP2 (GSK’214) inhibitors (Figure S2).
Discussion
Endothelial cells derived from stem cells have a plethora of
potential applications in pharmacology and regenerative medicine.
In the short term, the most important feature of any regenerated
vasculature must be a resistance to thrombosis. Without this
property, the graft would fail, as thrombi and clots prevent
adequate perfusion. However, in the longer term any vascular
graft needs to be resistant to atherosclerosis and restenosis.
The link between atherosclerosis and inflammation has been
known for some time. In 1988, a limited number of studies made
correlations between markers of bacterial infection and coronary
artery disease in man [26]. In line with these studies, others have
shown that Gram-negative Chlamydia is present in atherosclerotic
lesions [27]. These papers paved the way for early clinical trials
designed to assess the potential preventive benefits of antibiotic
therapy in atherosclerosis [28]. Whilst, on the whole, the clinical
trials with antibiotics were not successful in preventing cardiovas-
cular disease, the link between pathogens and atherosclerosis has
continued to be investigated. We now know the innate immune
receptors, TLR4 and TLR2, intrinsically regulate atherosclerosis
in animal models [7] and induce inflammatory responses in
human vascular cells [25,29].
We have previously shown that endothelial cells derived from
human stem cells (hESC-EC), have no functional TLR4 or TLR2
and, whilst it is beyond our current ability to test, we have
speculated that this may afford these cells an athero-protected
privilege over other endothelial cells derived from other stem cell
sources [10,11]. In the current study, we have confirmed our
previous observation that hESC-EC have no TLR4 response, but
that they have a fully functioning MyD88 pathway since they
respond avidly to IL-1b. We have gone on to perform a unique
comparison of the TLR4 response profile in endothelial cells
derived from the key stem cell sources, namely embryonic stem
cells, blood progenitor cells and induced pluripotent stem cells.
As with endothelial cells derived from adult [11,25] or foetal
vessels (HUVEC; this paper), but in direct contrast to endothelial
cells from embryonic stem cells (hESC-EC), we found the
endothelial cells derived from blood progenitors (BOEC), or
induced pluripotent stem cells (iPSC-EC), responded avidly to
Figure 3. Responses of hESC-EC and HUVEC to 24 hour infection with Heamophilus influenzae. (A) Effect of LPS (1 mg/ml) or C12-iE-DAP
(10 mg/ml) on CXCL8 release from hESC-EC and HUVEC after 24 hours. (B) Effect of Haemophilus influenzae (HIN) (105–108 CFU/ml) on CXCL8 release
from hESC-EC (solid line) or HUVEC (dashed line) after 24 hours. Data are mean 6 SEM; n= 3 representative of 6 hESC-EC isolations. Statistical
significance for responses to drugs or bacteria was determined by one-way ANOVA followed by Dunnett’s multiple comparison test (p,0.05).
doi:10.1371/journal.pone.0091119.g003
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LPS. These observations support the idea that hESC-EC may be
athero-protected, if remaining TLR4 resistant in vivo.
It is beyond the scope of this study or current technology to
investigate the long term stability of transplanted hESC-EC in
regard to atherosclerosis. However, we have used the technology
that is available currently and performed experiments to
determine the effect of the in vivo environment on TLR4
expression. This type of in vivo conditioning has been shown to
confer maturation of part-differentiated stem cells to fully mature
erythroid [30] or pancreatic islet cells [31]. As mentioned above,
in comparison with HUVEC, we found that hESC-EC had very
low TLR4 gene expression but relatively high NOD1. Similarly to
previous approaches [21,22], endothelial cells were injected into
Matrigel plugs implanted beneath the skin of nude rats. Nude rats
have compromised immune responses and so do not ‘reject’ the
human cell transplant. In our model, after the endothelial cells had
been incubated in vivo, we specifically measured human TLR4 and
NOD1 gene expression. This allowed us to differentiate PRR
expression in the human cells from those of the host (rat) cells.
Following in vivo conditioning, TLR4 expression remained low/
absent in hESC-EC. By contrast, NOD1 levels were stable in both
hESC-EC and HUVEC in vivo. Whilst not definitive, these
experiments are consistent with the idea that hESC-EC will retain
their TLR4-deficient phenotype in vivo, and supports our
hypothesis that, through this property, they would be resistant to
atherosclerosis.
NOD1 expression in hESC-EC was accompanied by a fully
functional cellular response to NOD1 agonists. Specifically, we
found that the NOD1 agonist C12-iE-DAP activated NF-kB and
induced cytokine release by hESC-EC. Importantly, the relative
sensitivity of hESC-EC to NOD1 agonists was similar to that seen
in endothelial cells derived from our other stem cell sources and in
HUVEC.
Whilst we speculate that absence of TLR function may result in
protection from atherosclerosis, it is important to recognise that
functionally, endothelial cells should be able to sense pathogens
Figure 4. Effect of pharmacological inhibition of RIP2 and NOD1 siRNA mediated knockdown on responses of hESC-EC to
Haemophilus influenzae (HIN) and C12-iE-DAP. (A) Relative expression (vs. GAPDH) of NOD1 following 48 hour incubation with NOD1 siRNA
normalized to non-targeting siRNA; n= 6. (B) CXCL8 release from hESC-EC following 48 hour pre-incubation with non-targeting siRNA (open bars) or
NOD1-siRNA (filled bars) and 24 hour treatment +/2 C12-iE-DAP (10 mg/ml) or Haemophilus influenzae (HIN) (107–108 CFU/ml); n = 7–8. (C) Effect of
GSK’214 (300 nM; RIP2 inhibitor) or GSK’217 (300 nM; NOD1 inhibitor), given 30 minutes before a 24 hour treatment with HIN (107 CFU/ml) or C12-iE-
DAP (10 mg/ml) on CXCL8 release; n = 4. It should be noted that GSK drugs increased CXCL8 release under basal conditions; for each experiment this
was subtracted from treatment groups. For panel A, statistical significance was determined by one-sample t-test. For panel B statistical significance
within siRNA groups was determined by one-way ANOVA followed by Dunnett’s multiple comparison test (*p,0.05), and between groups by two-
way ANOVA followed by Bonferroni’s post-test (+p,0.05). For panel C statistical significance for the effects of inhibitor of C12-iE-DAP or HIN induced
CXCL8 was determined by one-way ANOVA followed by Dunnett’s multiple comparison test (*p,0.05).
doi:10.1371/journal.pone.0091119.g004
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and mount an immune response. If endothelial cells are totally
insensitive to bacteria this may render a vessel or organ
‘immunosuppressed’. This is important to consider in cell/organ
therapy as post-organ transplant infection represents a major
clinical problem [32–34]. Our findings that hESC-EC could sense
NOD1 agonists, despite having no TLR4 function, led us to
consider that these cells had the potential to sense bacteria via the
NOD1 pathway. To test this we infected cells with Haemophilus
influenzae Gram-negative bacteria and found that despite no TLR4,
hESC-EC mounted a robust inflammatory response. This was
reduced in cells where NOD1 had been knocked down using
targeting siRNA, or by selective inhibition of NOD1 with a
prototype NOD1 inhibitor (GSK217; [25]), or inhibition of RIP2,
the obligatory signalling pathway for NOD receptors. This
indicates that, despite lack of TLR4 activation, hESC-EC are
capable of responding to Gram-negative bacteria via NOD1
pathways, and so would be functional to mount a defence when
incorporated into a graft.
In summary, we show that hESC-EC are unique amongst stem
cell-derived endothelial cells since they do not express functional
TLR4, even after in vivo conditioning. We show that, despite the
lack of TLR4, these cells can sense Gram-negative bacteria via a
fully functional NOD1 pathway. We speculate that endothelial
cells lacking TLR4 may be protected from atherosclerosis. It must
be noted however, that the role of NOD1 in atherosclerosis is not
yet known. Thus, whilst our results clearly show that TLR4
remains a deficient pathway in endothelial cells from embryonic
stem cells, our hypothesis should be viewed with caution until we
know more about (i) the fate of these cells in vivo in a disease
setting and (ii) NOD1 in vascular inflammation. Finally, it should
also be noted that the embryonic stem cell might not represent the
best stem cell progenitor in every therapeutic scenario especially
given their potential for allogenecity. We should then also consider
the potential to engineer ‘TLR4-deficient’ endothelial cells from
host stem cells such as those found in blood.
The initial data included here, showing more complete TLR4
responses in blood- and iPSC-derived endothelial cells is
interesting, and future experiments should aim to confirm whether
this is a systematic difference between hESC, iPSC and adult stem
cells. The idea of modifying stem cell-endothelial cells to improve
therapeutic utility is not new [10,35]. Thus, characterisation and
modification of stem cell-endothelial cells at the level of TLR4 and
other pattern recognition receptors represents a potentially
important target for optimal and tailored cell therapy design.
Supporting Information
Figure S1 Effect of NOD1 siRNA targeting on IL-1b
induced CXCL8 release. CXCL8 release from hESC-EC
following 48 hour pre-incubation with non-targeting siRNA (open
bars) or NOD1-siRNA (filled bars) and 24 hour treatment with/
without IL-1b (0.01–0.1 ng/ml). Data are mean6 SEM (n= 6–8).
(TIF)
Figure S2 Effect of GSK’214 and GSK’217 on IL-1b
induced CXCL8 release. CXCL8 release from hESC-EC
following 30 minute pre-incubation with GSK’214 (300 nM) or
GSK’217 (300 nM) and 24 hour treatment with/without IL-1b
(0.1 ng/ml). Data are mean 6 SEM (n= 4). Data were handled as
in Figure 4D.
(TIF)
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